A FIRST-IN-HUMAN TRIAL OF AN INTEGRIN BETA-6 TARGETED ANTIBODY-DRUG CONJUGATE (ADC), SGNB6A, IN PATIENTS WITH ADVANCED SOLID TUMORS: INTERIM RESULTS OF A PHASE 1 STUDY (SGNB6A-001)

被引：1

作者：

Hollebecque, Antoine ^{[1
]}

Lopez, Juanita ^{[2
]}

Piha-Paul, Sarina ^{[3
]}

Dowlati, Afshin ^{[4
]}

Patnaik, Amita ^{[5
]}

Galvao, Vladimir ^{[6
]}

Buckorny, Bruno ^{[7
]}

Sehgal, Kartik ^{[8
]}

Kingsley, Edwin ^{[9
]}

Sanborn, Rachel ^{[10
]}

Peters, Solange ^{[11
]}

Sun, Yan ^{[12
]}

Patilea-Vrana, Gabriela ^{[12
]}

Nazarenko, Natalya ^{[12
]}

Calvo, Emiliano ^{[13
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Royal Marsden Hosp Surrey, London, England

[3] Univ Texas Houston, Houston, TX USA

[4] Case Western Reserve Univ, Cleveland, OH USA

[5] START San Antonio, San Antonio, TX USA

[6] Vall dHebron Inst Oncol, Barcelona, Spain

[7] Beth Israel Deaconess Med Ctr, Boston, MA USA

[8] Dana Farber Canc Inst, Boston, MA USA

[9] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[10] Earle A Chiles Res Inst, Portland, OR USA

[11] CHU Vaudois, Lausanne, Switzerland

[12] Seagen Inc, Bothell, WA USA

[13] START Madrid CIOCC, Madrid, Spain

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0731

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

731

引用

页码：A763 / A763

页数：1

共 50 条

[41] First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors [J].

Shimizu, Toshio ;

Fujiwara, Yutaka ;

Yonemori, Kan ;

Koyama, Takafumi ;

Sato, Jun ;

Tamura, Kenji ;

Shimomura, Akihiko ;

Ikezawa, Hiroki ;

Nomoto, Maiko ;

Furuuchi, Keiji ;

Nakajima, Ryo ;

Miura, Takuma ;

Yamamoto, Noboru .

CLINICAL CANCER RESEARCH, 2021, 27 (14) :3905-3915

[42] Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors [J].

Chandana, S. ;

Garmezy, B. ;

Dowlati, A. ;

Sharma, M. R. ;

Henner, W. ;

Robinson, R. ;

Hingorani, P. ;

Jeng, E. ;

Papadopoulos, K. P. .

ANNALS OF ONCOLOGY, 2023, 34 :S1077-S1077

[43] Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors [J].

Subbiah, V. ;

Falchook, G. ;

Davis, A. A. ;

Wang, J. S. ;

de Miguel, M. ;

Santoro, A. ;

Maur, M. ;

Aljumaily, R. ;

Boni, V. ;

de Speville, B. Doger ;

Sun, Y. ;

Du, Y. ;

Lakshmikanthan, S. ;

Bedse, G. ;

Ward, A. ;

Zweidler-McKay, P. ;

Gandhi, L. .

EUROPEAN JOURNAL OF CANCER, 2024, 211 :S72-S73

[44] A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors [J].

O'Cearbhaill, Roisin Eilish ;

Barve, Minal A. ;

Darus, Christopher ;

Gabrail, Nashat Y. ;

Johannet, Paul ;

Loh, Jade ;

Lerose, Marybeth ;

Andreas, Karen ;

Ullmann, Claudio Dansky .

JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (16_SUPPL) :TPS2685-TPS2685

[45] Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors [J].

Sharma, Manish ;

Kuboki, Yasutoshi ;

Camidge, D. Ross ;

Perets, Ruth ;

Sommerhalder, David ;

Yamamoto, Noboru ;

Bar, Jair ;

Parikh, Apurvasena ;

Li, Rui ;

Thiele, Gladys Morrison ;

Aristide, Martha Raluca Neagu ;

Freise, Kevin Jay ;

Powderly, John D. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[46] First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors [J].

Sommerhalder, David ;

Hamilton, Erika P. ;

Mukohara, Toru ;

Yonemori, Kan ;

Mita, Monica M. ;

Yamashita, Toshinari ;

Zheng, Jenny ;

Liu, Li ;

Maity, Arnab K. ;

Mishra, Natasha Homji ;

Bogg, Orlaith ;

Li, Meng ;

LoRusso, Patricia .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[47] First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors [J].

Zhang, Jian ;

Du, Yiqun ;

Meng, Yanchun ;

Liu, Xiaojun ;

Mu, Yuxin ;

Liu, Yunpeng ;

Shi, Yehui ;

Wang, Jufeng ;

Zang, Aimin ;

Gu, Shanzhi ;

Liu, Tianshu ;

Zhou, Huan ;

Guo, Hongqian ;

Xiang, Silong ;

Zhang, Xialu ;

Wu, Suqiong ;

Qi, Huanhuan ;

Li, Mengke ;

Hu, Xichun .

NPJ PRECISION ONCOLOGY, 2024, 8 (01)

[48] First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors. [J].

Ameratunga, Malaka ;

Harvey, R. Donald ;

Mau-Sorensen, Morten ;

Thistlethwaite, Fiona ;

Forssmann, Ulf ;

Gupta, Manish ;

Johannsdottir, Hrefna ;

Ramirez-Andersen, Terrie ;

Bohlbro, Mika Linette ;

Losic, Nedjad ;

Ervin-Haynes, Annette L. ;

Lopez, Juanita Suzanne ;

Vergote, Ignace .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[49] First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid [J].

Lin, F. ;

Huang, Y. ;

Lu, Y. ;

Rao, X. ;

Wang, X. ;

Wang, F. ;

Huang, X. .

ANNALS OF ONCOLOGY, 2024, 35 :S354-S355

[50] First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors. [J].

Bendell, Johanna ;

Blumenschein, George ;

Zinner, Ralph ;

Hong, David ;

Jones, Suzanne ;

Infante, Jeffrey ;

Burris, Howard ;

Rajagopalan, Prabhu ;

Kornacker, Martin ;

Henderson, David ;

Kelly, Andrea ;

Hassan, Raffit .

CANCER RESEARCH, 2013, 73 (08)

← 1 2 3 4 5 →